Castle Biosciences (NASDAQ:CSTL) Research Coverage Started at Guggenheim
Guggenheim assumed coverage on shares of Castle Biosciences (NASDAQ:CSTL – Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $25.00 price target on the stock. Castle Biosciences Stock Down 2.6 % Shares of Castle Biosciences stock opened at $20.07 on Thursday. The firm has a market […]
More Stories
Significant Increase in the Circulation of Counterfeit Bills in Retail Stores
By The Canadian Press The Retail Council of Canada is sounding the alarm about the significant increase in circulation of...
White House Economist Proposal Coming Soon on $2,000 Tariff Rebate Checks
By Jack Phillips A top White House economic official said that it appears more and more likely that the Trump...
Malicious Actors Impersonating Senior US Officials, FBI Warns
By Naveen Athrappully Malicious actors are impersonating government officials to secure sensitive information and steal funds, the FBI said in...
DOJ Says It Re-released 119 Pages of Epstein Files That Were Redacted
By Jack Phillips The Department of Justice (DOJ) on Sunday re-released with “minimal redactions” 119 pages of grand jury materials...
Why Some Doctors Are Turning Against Vaccine Mandates
By Zachary Stieber For Dr. Anish Koka, vaccine mandates made sense. He has a daughter who received an organ transplant,...
Wall Street Review: Stocks End Week Mixed Amid Bulls-Bears Tug of War
By Panos Mourdoukoutas Equities finished the week mixed as a renewed tug-of-war played out between bullish investors focused on the...